IL6R and neoplasm: Agents blocking IL-6/IL-6R or inhibiting JAK/STAT3 to block tumor progression have been or are being tested in clinical trials, such as siltuximab (an anti-IL-6 mAb), tocilizumab (an anti-IL-6R mAb), Ruxolitinib (a JAK signaling inhibitor).